Improved early prognostic algorithm for hepatocellulcar carcinoma

改进的肝细胞癌早期预后算法

• 批准号: 10356129
• 负责人: Amy K Kim
• 金额: $ 26.19万
• 依托单位: JOHNS HOPKINS UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-04-01 至 2025-03-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10356129
• 关键词: Algorithms; Asian Americans; Biological Markers; Black Populations; Blood; Blood Vessels; Blood specimen; Carcinoma; Cells; Cessation of life; Characteristics; Cirrhosis; Clinical; Clinical Data; Data; Deterioration; Development; Disease; Disease Progression; Early treatment; Enrollment; Epidemiology; Face; Fibrinogen; Functional Imaging; Genomics; Goals; Hepatitis C; Hispanic Populations; Hospitals; Image; Immune; Incidence; Individual; Instruction; Intervention; K-Series Research Career Programs; Laboratories; Link; Liver; Liver diseases; Malignant Neoplasms; Measurement; Measures; Mentors; Metabolic syndrome; Natural History; Neoadjuvant Therapy; Neoplasm Circulating Cells; Obesity Epidemic; Outcome; Patient-Focused Outcomes; Patients; Performance; Persons; Plasma; Positioning Attribute; Primary carcinoma of the liver cells; Prognosis; Prognostic Factor; Prognostic Marker; Research; Resources; Risk; Risk Factors; Role; Sampling; Scientist; Screening for cancer; Solid; Specimen; Staging; Supervision; Techniques; Testing; Therapeutic; Time; Training; Transplant Recipients; Transplantation; Tumor Burden; Tumor Volume; Waiting Lists; Work; biobank; biomarker development; blood-based biomarker; career; circulating biomarkers; clinical biomarkers; clinical risk; detection test; effective therapy; end stage liver disease; experience; improved; individualized medicine; liquid biopsy; liver function; liver transplantation; multidisciplinary; non-alcoholic fatty liver disease; novel; organ allocation; outcome prediction; patient population; personalized approach; personalized medicine; prediction algorithm; predictive tools; primary outcome; prognostic algorithm; prognostic value; prognostication; prospective; radiological imaging; secondary outcome; skills; translational scientist; transplant centers; treatment guidelines; treatment response; tumor; tumor DNA; tumor growth; tumor progression

PROJECT SUMMARY/ABSTRACT This is an application for a Mentored Clinician Scientist Research Career Development Award. The goal of the proposed project is to provide the candidate with advanced skills needed to transition to an independent translational investigator with focus on accurate prognostic biomarkers and development of a tailored treatment algorithm in HCC. To facilitate this long-term career goal the candidate will examine multiple imaging, clinical and blood-based biomarkers, and investigate the role of liquid biopsy in HCC progression in liver transplant-eligible patients. The candidate proposes a comprehensive training plan, combining didactic instruction overseen by her mentors, formal coursework, participation in applied training experiences with individual mentors/advisors, and supervised performance of relevant laboratory techniques. The proposed study will enroll HCC patients listed for liver transplantation and follow until the time of transplantation or disease progression and death. She will identify the determinants contributing to the disparate outcomes by including novel functional imaging, clinical risk factors and circulating biomarkers including circulating tumor cells, immune cells and tumor DNA. This application provides a more tailored approach to patient management in the limited time available, to offer effective therapy to patients who are challenged with a lethal cancer and end-stage liver disease. It would also improve liver transplant organ allocation, thus improving overall therapeutic value for liver transplant recipients.

项目摘要/摘要 这是一份临床医生导师科学家研究职业发展奖的申请书。 拟议项目的目标是为应聘者提供所需的高级技能 过渡到专注于准确预测的独立翻译调查员 肝细胞癌的生物标志物和个体化治疗算法的发展。为了促进这一长期的 职业目标候选人将检查多个成像、临床和血液生物标记物， 并研究液体活检在符合肝移植条件的患者肝细胞癌进展中的作用。 候选人提出了一个全面的培训计划，结合教学指导监督 由她的导师，正规的课程作业，参加应用培训的经验与个人 相关实验室技术的导师/顾问和受监督的操作。建议数 这项研究将招募肝移植患者，并将一直跟踪到 移植或疾病进展和死亡。她将找出决定因素 通过包括新的功能成像、临床风险因素和 循环生物标志物包括循环肿瘤细胞、免疫细胞和肿瘤DNA。这 应用程序在有限的可用时间内为患者管理提供了一种更定制的方法， 为患有致命癌症和终末期肝脏的患者提供有效的治疗 疾病。它还将改善肝脏移植器官的分配，从而提高整体治疗效果 对肝移植受者的价值。